Compare PFO & VRCA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PFO | VRCA |
|---|---|---|
| Founded | 1991 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 118.6M | 137.3M |
| IPO Year | N/A | 2018 |
| Metric | PFO | VRCA |
|---|---|---|
| Price | $9.14 | $5.73 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $17.00 |
| AVG Volume (30 Days) | ★ 36.2K | 35.3K |
| Earning Date | 01-01-0001 | 05-11-2026 |
| Dividend Yield | ★ 6.51% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $35,577,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $94.44 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 370.22 |
| 52 Week Low | $8.85 | $0.52 |
| 52 Week High | $9.90 | $9.82 |
| Indicator | PFO | VRCA |
|---|---|---|
| Relative Strength Index (RSI) | 49.45 | 44.47 |
| Support Level | $8.95 | $5.27 |
| Resistance Level | $9.27 | $6.48 |
| Average True Range (ATR) | 0.08 | 0.49 |
| MACD | 0.01 | -0.01 |
| Stochastic Oscillator | 51.11 | 19.17 |
Flaherty & Crumrine Prfd Income Oppo is the United States-based diversified, closed-end management investment company. Its primary investment objective is to provide its common shareholders with high current income consistent with the preservation of capital. The fund invests in a diversified portfolio of preferred securities which includes traditional preferred stocks eligible for the inter-corporate dividends received a deduction and fully taxable preferred securities.
Verrica Pharmaceuticals Inc is a therapeutics company developing and commercializing medications for the treatment of dermatologic diseases, including skin cancers. Its commercial product and portfolio of product candidates are clinician administered therapies in areas of high unmet need. This product portfolio consists of one product with an approved indication for molluscum contagiosum, or molluscum, with the potential for several follow-on indications, as well as additional pipeline product candidates. Its commercial product, YCANTH (VP-102), for the treatment of molluscum in adult and pediatric patients two years of age and older. YCANTH (VP-102) is a proprietary drug-device combination that contains a GMP-controlled formulation of cantharidin.